Innovation in Translational Rodent Models of Colitis

Presented By: 
Caitlin Parello
Gregory Lyng

Overview: Crohn’s disease (CD) and Ulcerative Colitis (UC) belong to the family of Inflammatory Bowel Diseases (IBD) and affect up to 0.1% of the population in developed countries. Currently, there are no curative therapies available for IBD, only treatments intended to achieve and maintain remission from active flares of inflammation. With the use of biologic therapies still on the rise, the total drug market size for IBD is currently estimated to be somewhere between $8.5-10 billion dollars annually and rising.

As the prevalence of IBD and the corresponding drug market continues to grow, there is urgency to understand the underlying pathobiology as a way to develop new drug targets and potential therapies. The use of predictive animal models that accurately replicate the human disease state and intestinal microbiome are essential to this process.

This webinar discusses several sophisticated pre-clinical animal models of IBD. Included in this discussion are both the classical, chemically-induced models, as well as more involved approaches of modeling using immunological based methods (e.g. adoptive transfer). We will discuss these models as they present in both standard rodent models as well as those models where the gut microbiome is either completely naïve (germ-free) or has been modified and/or reconstituted with known bacteria (gnotobiotic). We will also discuss novel data collection approaches that can be used to provide clinically relevant and actionable results that will directly aid in the drug development process.